July 19, 2007 -- Sinobiomed (OTC BB: SOBM.OB) has begun producing recombinant acidic Fibroblast Growth Factor (aFGF), a treatment for ulceration. The company will launch aFGF in August 2007 with a production volume of approximately 20 million boxes per year. Sinobiomed also reported that its recombinant batroxobin (rBAT), an anti-bleeding agent, completed the first of two parts of a Phase II trial, involving 120 patients; it will now enter a 400-patient trial. More details...
